Changes Afoot for Vaccine Production in Russia

February 3, 2015

Share

The Russian Ministry of Health plans to bring all Russian vaccine producers into a single national immune-biological cluster in 2015.

In Russia, the market for the vaccines included in the National Immunization Schedule is quite a special segment of the pharmaceutical market. The main buyer of prophylactic vaccines is the State, which is also the main market regulator. Over 90% of the total supply in the targeted vaccine market is purchased by the Ministry of Health and Social Development of the Russian Federation, and its price is adjusted through a listing in vital and essential drugs register.

According to data collected by Evaluate Pharma, the sales volume of the global vaccine market was $25.6 billion at the end of 2013. In 2020 this number is expected to rise to $41.3 billion.

According to the new plan, all vaccines should be developed and produced in Russia, which will have implication for international companies. Thus, the current main research centers, large enterprises and small companies have to form a single structure. This new organization is expected to not only be able to produce vaccines for the consumption in Russia, but also for export.

Based on the National Immunization Schedule, 22 types of vaccines are currently purchased. 18 of them are produced in Russia, 1 type is produced inside the country using key foreign ingredients and 3 vaccine types are imported. In monetary terms, 65% of the Russian vaccine market is made up by immunological foreign products and it is the state’s main objective to localize the production of these vaccines.

The majority of the vaccines created in the Soviet times are outdated and should be upgraded at least to the level of their foreign counterparts. Today, improvements to the National Immunization Schedule are only possible through the import of vaccines.

These new plans will be very interesting to monitor.